Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division ... Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States. Show more
CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study PR Newswire RARITAN, N.J., July 2...
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients PR Newswire HELSINKI, June 28, 2024...
Beasley Allen: ‘We believe this decision should spell doom for J&J’s third bankruptcy plan’ The U.S. Supreme Court has denied a $7 billion Purdue Pharmaceuticals bankruptcy plan which would...
Acquisition includes two pre-clinical bispecific antibodies targeting proven disease pathways, offering the potential to transform the treatment paradigm for patients living with atopic...
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease PR Newswire SPRING HOUSE, Pa...
Attorney: “The stakes are even higher for the very fabric of our civil justice system” Some of the nation’s largest law firms recognized for their committed and successful representation of...
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction PR Newswire SPRING HOUSE, Pa., June 20, 2024 TREMFYA®...
Trump Media & Technology Group (NASDAQ:DJT) – Trump Media & Technology Group announced that the SEC approved the resale of shares and warrants, expecting to raise about $247...
Class action lawsuit demands compensation for future talc-related injuries and medical monitoring of talcum powder users Plaintiffs who are at increased risk of ovarian cancer due to long-term...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -3.15 | -2.11154310229 | 149.18 | 149.2 | 144.84 | 5692363 | 146.58465146 | CS |
4 | -1.37 | -0.929443690638 | 147.4 | 149.7199 | 143.88 | 6675424 | 146.96107164 | CS |
12 | -5.52 | -3.64236225668 | 151.55 | 154.86 | 143.13 | 7717679 | 148.08083568 | CS |
26 | -10.77 | -6.86862244898 | 156.8 | 163.58 | 143.13 | 7396905 | 153.54902662 | CS |
52 | -18.32 | -11.1469425008 | 164.35 | 175.97 | 143.13 | 11180271 | 161.14644051 | CS |
156 | -19.99 | -12.0407179858 | 166.02 | 186.69 | 143.13 | 8506429 | 165.03785255 | CS |
260 | 6.81 | 4.89153857204 | 139.22 | 186.69 | 109.16 | 8177065 | 157.85038324 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.